Adage Capital Partners GP L.L.C. Has $39.56 Million Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Adage Capital Partners GP L.L.C. increased its stake in Kenvue Inc. by 141.5%, owning 1,649,758 shares valued at approximately $39.56 million as of the end of the 1st quarter.
• Kenvue's recent earnings report showed an **EPS of $0.29**, which beat estimates, although revenue declined by 4% year-over-year to **$3.84 billion**.
• The company recently raised its quarterly dividend to **$0.2075**, yielding **4.1%**, indicating strong shareholder returns despite a high dividend payout ratio of 112.16%.

Adage Capital Partners GP L.L.C. increased its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 141.5% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,649,758 shares of the company's stock after acquiring an additional 966,500 shares during the quarter. Adage Capital Partners GP L.L.C. owned approximately 0.09% of Kenvue worth $39,561,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of KVUE. Pittenger & Anderson Inc. acquired a new stake in shares of Kenvue in the first quarter valued at about $30,000. TruNorth Capital Management LLC purchased a new position in shares of Kenvue in the first quarter valued at approximately $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue in the first quarter valued at approximately $37,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after acquiring an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich raised its holdings in Kenvue by 120.6% in the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after acquiring an additional 929 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 1.0%

Shares of NYSE:KVUE traded down $0.18 during midday trading on Monday, reaching $18.44. The company had a trading volume of 55,855,744 shares, compared to its average volume of 18,090,848. The company has a fifty day simple moving average of $21.37 and a two-hundred day simple moving average of $22.38. The firm has a market cap of $35.39 billion, a price-to-earnings ratio of 24.92, a price-to-earnings-growth ratio of 2.67 and a beta of 0.83. Kenvue Inc. has a 1-year low of $17.15 and a 1-year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period last year, the company posted $0.32 EPS. The business's quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This is a boost from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. Kenvue's dividend payout ratio is 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of recent research reports. Canaccord Genuity Group cut their target price on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Citigroup decreased their target price on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Bank of America cut their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Evercore ISI cut their target price on shares of Kenvue from $25.00 to $23.00 and set an "in-line" rating for the company in a research note on Monday. Finally, Zacks Research upgraded Kenvue to a "strong sell" rating in a report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $24.21.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.